FDA Rejects Summit's Ivonescimab in Lung Cancer, Denying a First-in-Class Shot
The FDA handed Summit Therapeutics a complete response letter for ivonescimab, its PD-1xVEGF bispecific, in EGFR-mutated NSCLC after TKI treatment. Regulators wanted a statistically significant overall survival win, and the HARMONi trial didn't deliver one. Approval would have been a first in the U.S. for the drug class.
- 4 sources report it: biospace.com, statnews.com, seekingalpha.com, bloomberg.com.
- The source published it on Nov 15, 2026 at 6:04 AM.
Nothing open. Every check passed.
The FDA turned down Summit Therapeutics' biologics license application for ivonescimab in EGFR-mutated non-small cell lung cancer following TKI treatment, issuing a complete response letter that said the application cannot be approved in its present form. The agency's core objection: Summit hasn't established evidence of effectiveness, because the therapy failed to show a statistically significant overall survival benefit. The FDA said a progression-free survival gain made 'in the absence of a statistically significant OS benefit' does not demonstrate a positive benefit-risk profile.
'We are disappointed for patients and their families awaiting additional treatment options in this setting,' Summit co-CEO Robert Duggan said in a Sunday statement. Duggan said the company chose to pursue the ivonescimab regimen to give patients another option, and that the global HARMONi study gave Summit the basis for a treatment these patients needed. The company did not lay out next steps for the EGFR indication in that release.
The application rested on the Phase 3 HARMONi trial, where ivonescimab plus chemotherapy improved progression-free survival compared with placebo and, for the first time, replicated in Western patients what had been seen in China. But the readout was mixed, with the drug missing on overall survival. Summit went back to the FDA in September with extra data showing a slight OS benefit across the overall global population, and analysts had grown bullish that approval would follow. It wasn't enough.
Summit said it will keep building the evidence base for ivonescimab across multiple indications, including several types of NSCLC. In China, partner Akeso has sold the drug for this indication since 2024 and is running studies at all phases in small cell lung cancer, biliary tract cancer, head and neck cancer and gastroesophageal junction cancer.
The rejection lands on a drug analysts have talked up loudly. Graig Suvannavejh, managing director and senior biotech and biopharma analyst at Mizuho Securities, told BioSpace earlier this month that the asset is 'the next major backbone' of cancer treatment, with AstraZeneca, Pfizer and Revolution Medicines among the companies angling to get in on the Akeso-partnered antibody. Analysts have also floated it as a potential 'Keytruda killer' after it beat Merck's blockbuster in a head-to-head NSCLC trial in China — though Keytruda holds approvals in more than 40 indications, and analysts expect the overall PD-1xVEGF market to hit $30 billion by 2032. Evaluate pegs ivonescimab specifically at $4.4 billion across several indications by 2030.
Summit itself was built as a NewCo around the drug through its Akeso partnership, making it one of the most prominent biotechs assembled via a licensing deal with a Chinese company. That playbook has swept the industry: China captured 56% of all total licensing deal value so far this year, up from just 10% in 2021, as the country pushes to become the leading source of innovative medicines globally.
TopicsSummit Therapeutics · ivonescimab · FDA · Akeso · Robert Duggan · Keytruda · Merck · AstraZeneca
Written by AI from verified reporting. Not financial advice.

